Shamburg News · 8-K filed Nov 10, 2026, 5:15 PM EST

CorMedix to Acquire Substantially All Assets of Heron Therapeutics in Asset Purchase Deal

CRMD · CorMedix Inc.

  • Acquisition
  • Financing
  • Material agreement
  • Reg FD disclosure
  • Materiality: high

On November 9, 2026, CorMedix Inc. and Heron Therapeutics, Inc. announced a definitive asset purchase agreement under which CorMedix will acquire substantially all of Heron's assets. The filing furnishes an investor call transcript and investor presentation (Exhibits 99.1 and 99.2) describing the transaction. The investor call transcript describes upfront consideration of $145 million in cash plus approximately 14.6 million CorMedix shares, a $150 million Pharmakon term loan facility, and $45 million to $60 million in targeted annual operating cost synergies by year-end 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001213900-26-118109.

Written from the filing by Shamburg Markets. Figures are as reported by the company.